Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 3.9%

Dermata Therapeutics, Inc. (NASDAQ:DRMAGet Free Report)’s share price fell 3.9% on Thursday . The company traded as low as $3.25 and last traded at $3.48. 25,028 shares traded hands during trading, a decline of 42% from the average session volume of 42,946 shares. The stock had previously closed at $3.62.

Dermata Therapeutics Trading Down 3.9 %

The firm has a market cap of $1.53 million, a P/E ratio of -0.13 and a beta of 0.89. The firm has a 50-day simple moving average of $5.32 and a 200-day simple moving average of $7.39.

Dermata Therapeutics (NASDAQ:DRMAGet Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($3.15) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dermata Therapeutics stock. Acadian Asset Management LLC increased its stake in Dermata Therapeutics, Inc. (NASDAQ:DRMAFree Report) by 34.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,538 shares of the company’s stock after purchasing an additional 19,253 shares during the period. Acadian Asset Management LLC owned 2.37% of Dermata Therapeutics worth $79,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

Read More

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with's FREE daily email newsletter.